Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SCYX vs AQST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AQST Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–4 Matrix Metrics)

AQST Overall Winner 6-Pillar Tally: SCYX 2 – 3 AQST (1 Tie) Matrix Metrics: SCYX 4 – 6 AQST

As of Nov 20, 2026, Aquestive Therapeutics, Inc. (AQST) is the stronger overall head-to-head candidate over SCYNEXIS, Inc. (SCYX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SCYX carries a Unified Composite Score of 42.2/100 (HOLD) at $2.38 (1.9x Forward P/E, -126.9% operating margin), whereas AQST carries 62.9/100 (BUY) at $3.46 (N/M Forward P/E, -114.1% operating margin).

  • Technical & Structure Timing Caution: SCYX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 19.2); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SCYX vs AQST
SCYX NASDAQ
SCYNEXIS, Inc.
Pharmaceutical Preparations
$2.38
-8.64% 1D
Market Cap $25.9M
TTM Revenue $19M
Forward P/E 1.9x
Beta / 30D Vol 3.09β · 73% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 65.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.2%), weak momentum, RSI 19
RSI-14: 19.2 · SMA20: $3.41 · SMA50: $3.98
AQST NASDAQ Head-to-Head Winner
Aquestive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.46
-6.61% 1D
Market Cap $465.7M
TTM Revenue $49M
Forward P/E N/M
Beta / 30D Vol 0.89β · 56% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 54.0 Fund 68.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 36
RSI-14: 36.5 · SMA20: $3.77 · SMA50: $4.23

6-Pillar Scorecard Institutional Category Breakdown (SCYX 2 – 3 AQST)

Columns: Metric · SCYX · AQST
1. Valuation Multiples SCYX
Forward P/E 1.9x N/M
Trailing P/E 1.9x N/M
PEG Ratio N/M N/M
EV / Revenue 1.0x 8.9x
2. Growth & Scale AQST
Revenue Growth (YoY) -82.8% -41.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $19M $49M
Market Cap $25.9M $465.7M
3. Profitability & Quality AQST
Gross Margin 100.0% 65.3%
Operating Margin -126.9% -114.1%
Net Profit Margin -53.5% -162.3%
Return on Equity (ROE) -21.2% 0.0%
4. Balance Sheet & Cash Flow SCYX
Cash Generation (TTM) -$12M -$41M
Cash Flow Margin -63.8% -83.3%
Net Cash / Leverage $6.4M Net Cash $32M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AQST
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 47.2% (4th %ile) 87.9% (64th %ile)
Put/Call OI Skew 20.50x (Put-Skewed) 0.98x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SCYX (4) vs AQST (6)
Institutional Metric SCYX AQST Criterion Row Edge
Market Capitalization
Scale
$25.9M $465.7M Larger Scale AQST
Trailing P/E Ratio
Valuation
1.9x N/M Lower Multiple SCYX
Forward P/E Ratio
Valuation
1.9x N/M Lower Multiple SCYX
Revenue Growth (YoY)
Growth
-82.8% -41.0% Higher Growth AQST
Operating Margin (TTM)
Profitability
-126.9% -114.1% Higher Margin AQST
Net Profit Margin
Profitability
-53.5% -162.3% Higher Margin SCYX
Return on Equity (ROE)
Capital Efficiency
-21.2% 0.0% Higher ROE AQST
52-Week Range Position
Momentum
33% ($1–$6) 14% ($3–$7) Stronger Trend SCYX
Beta / 30D Volatility
Risk Regime
3.09β · 73% Vol 0.89β · 56% Vol Lower Realized Risk AQST
Unified Institutional Score
Composite Signal
42.2 / 100 (HOLD) 62.9 / 100 (BUY) Higher Composite AQST
Trailing 12M Revenue (USD)
Operating Scale
$19M $49M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 65.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.0x EV/Rev N/M PEG · 8.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$12M ($6.4M Net Cash) -$41M ($32M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AQST +21.31 pp
SCYX: -37.53% · AQST: -16.22%
3M Horizon AQST +26.83 pp
SCYX: -54.75% · AQST: -27.92%
6M Horizon SCYX +241.47 pp
SCYX: +225.45% · AQST: -16.02%
1Y Horizon SCYX +344.04 pp
SCYX: +303.39% · AQST: -40.65%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SCYX Revenue AQST Revenue SCYX Op. Margin AQST Op. Margin Margin Leader
FY2018 $0M $70M -11666.5% -72.6% AQST
FY2019 $0M $50M -40430.6% -100.1% AQST
FY2020 N/A $50M N/A -93.6% AQST
FY2021 $10M $50M -462.2% -68.2% AQST
FY2022 $10M $50M -1684.5% -88.2% AQST
FY2023 $140M $50M 51.9% -29.9% SCYX
FY2024 $0M $60M -990.8% -53.5% AQST
FY2025 $20M $40M -78.0% -159.5% SCYX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SCYX BREAKDOWN
77d in phase · OBV NEUTRAL
Current IV 47.2%
IV Percentile 4th %ile
Put/Call OI Skew 20.50x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact SCYX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AQST BREAKDOWN
61d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 64th %ile
Put/Call OI Skew 0.98x (Balanced)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AQST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SCYX Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $25.9M market capitalization and -126.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AQST Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $465.7M market capitalization and -114.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SCYX vs AQST Key Questions & Quantitative Answers

As of Nov 20, 2026, Aquestive Therapeutics, Inc. (AQST) is the stronger overall head-to-head candidate over SCYNEXIS, Inc. (SCYX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SCYX carries a Unified Composite Score of 42.2/100 (HOLD) at $2.38 (1.9x Forward P/E, -126.9% operating margin), whereas AQST carries 62.9/100 (BUY) at $3.46 (N/M Forward P/E, -114.1% operating margin). Technical & Structure Timing Caution: SCYX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 19.2); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AQST leads the Growth & Scale pillar: SCYX posts -82.8% YoY revenue growth and +0.0% YoY earnings growth on $19M TTM revenue (100.0% gross margin, -126.9% operating margin), compared with AQST at -41.0% YoY revenue growth and +0.0% YoY earnings growth on $49M TTM revenue (65.3% gross margin, -114.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SCYX cumulative revenue shifted +100.0% while AQST shifted -42.9%. In operating R&D and SG&A reinvestment, SCYX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AQST.

SCYX screens cheaper on headline valuation multiples. SCYX trades at 1.9x Forward P/E, 1.9x Trailing P/E, N/M PEG, and 1.0x EV/Revenue (-63.8% FCF margin), whereas AQST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.9x EV/Revenue (-83.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SCYX (-21.2% ROE) versus AQST (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, SCYX carries 47.2% implied volatility (4th %ile, Compressed (<25th %ile)), a 20.50x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (3.09β · 73% Vol realized risk). By comparison, AQST carries 87.9% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 0.98x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 56% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.